These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 30017783

  • 1. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
    Liu G, Ouyang Q, Xia F, Fan G, Yu J, Zhang C, Wang D.
    HPB (Oxford); 2019 Jan; 21(1):107-113. PubMed ID: 30017783
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, Han KH, Chon CY, Park JY.
    BMC Cancer; 2013 Jan 03; 13():5. PubMed ID: 23282286
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J, Gan Y, Ren Z, Ye S.
    Ann Surg Oncol; 2012 Oct 03; 19(11):3540-6. PubMed ID: 22532305
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU, Korean TACE Study Group.
    Yonsei Med J; 2021 Jan 03; 62(1):12-20. PubMed ID: 33381930
    [Abstract] [Full Text] [Related]

  • 5. Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.
    Cerban R, Ester C, Iacob S, Grasu M, Pâslaru L, Dumitru R, Lupescu I, Constantin G, Croitoru A, Gheorghe L.
    J Gastrointestin Liver Dis; 2018 Dec 03; 27(4):409-417. PubMed ID: 30574623
    [Abstract] [Full Text] [Related]

  • 6. Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.
    Eltawil KM, Berry R, Abdolell M, Molinari M.
    HPB (Oxford); 2012 Mar 03; 14(3):162-70. PubMed ID: 22321034
    [Abstract] [Full Text] [Related]

  • 7. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
    Yoon HM, Kim JH, Kim EJ, Gwon DI, Ko GY, Ko HK.
    J Vasc Interv Radiol; 2013 Nov 03; 24(11):1639-46. PubMed ID: 23962438
    [Abstract] [Full Text] [Related]

  • 8. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS, Lim TS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baatarkhuu O, Kim SU.
    Dig Dis Sci; 2019 Dec 03; 64(12):3660-3668. PubMed ID: 31187326
    [Abstract] [Full Text] [Related]

  • 9. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma.
    Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, Cho SK, Shin SW, Carriere KC, Ahn JH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW.
    Clin Mol Hepatol; 2016 Jun 03; 22(2):250-8. PubMed ID: 27377909
    [Abstract] [Full Text] [Related]

  • 10. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I.
    World J Gastroenterol; 2015 May 14; 21(18):5654-62. PubMed ID: 25987792
    [Abstract] [Full Text] [Related]

  • 11. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT.
    Eur J Gastroenterol Hepatol; 2018 Jan 14; 30(1):44-53. PubMed ID: 29076939
    [Abstract] [Full Text] [Related]

  • 12. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R, Gan Y, Ge N, Chen Y, Wang Y, Zhang B, Wang Y, Ye S, Ren Z.
    J Vasc Interv Radiol; 2016 Dec 14; 27(12):1829-1836. PubMed ID: 27553917
    [Abstract] [Full Text] [Related]

  • 13. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization.
    Sadick M, Haas S, Loehr M, Elshwi M, Singer MV, Brade J, Schoenberg SO, Diehl SJ.
    Onkologie; 2010 Dec 14; 33(1-2):31-7. PubMed ID: 20164659
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
    Sanoff HK, Chang Y, Stavas JM, Stürmer T, Lund J.
    J Natl Compr Canc Netw; 2015 Sep 14; 13(9):1102-10. PubMed ID: 26358794
    [Abstract] [Full Text] [Related]

  • 15. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
    Tian M, Zhang X, Huang G, Fan W, Li J, Zhang Y.
    Abdom Radiol (NY); 2019 Oct 14; 44(10):3304-3311. PubMed ID: 31250181
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ, Chen JZ, Li ZH, Bai T, Chen J, Zhu SL, Li LQ, Wu FX.
    World J Gastroenterol; 2017 Nov 07; 23(41):7415-7424. PubMed ID: 29151695
    [Abstract] [Full Text] [Related]

  • 17. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Jeong Y, Yoon SM, Han S, Shim JH, Kim KM, Lim YS, Lee HC, Kim SY, Park JH, Lee SW, Ahn SD, Choi EK, Kim JH.
    PLoS One; 2015 Nov 07; 10(8):e0135298. PubMed ID: 26252472
    [Abstract] [Full Text] [Related]

  • 18. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L, Gou CY, Li JY, Achakzai R, Li XH.
    Hepatobiliary Pancreat Dis Int; 2016 Apr 07; 15(2):152-7. PubMed ID: 27020631
    [Abstract] [Full Text] [Related]

  • 19. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.
    Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M.
    Eur J Gastroenterol Hepatol; 2019 Nov 07; 31(11):1414-1423. PubMed ID: 31045613
    [Abstract] [Full Text] [Related]

  • 20. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC, Hung YW, Liu CA, Lee RC, Su CW, Huo TI, Li CP, Chao Y, Lin HC, Hou MC, Huang YH.
    Liver Int; 2019 Sep 07; 39(9):1704-1712. PubMed ID: 31319016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.